Subcutaneous (SC) tumor models have played an important role in cancer drug discovery for many years. The use of these models is a critical step along the drug discovery cascade. In vivo studies utilizing SC tumor models are incorporated into pharmacodynamic assays to ensure target inhibition and adequate inhibition of target over time.

The deep tissue location of the tumors in many orthotopic models makes the assessment of anti-cancer activity difficult without the use of imaging techniques. Traditional methods require the sacrifice of large cohorts of animals, at different time points, to track tumor progression, metastatic spread and response to therapy. 

Metastatic disease accounts for the majority of cancer-related mortalities. The genes and proteins involved in metastasis have long been sought after as potential therapeutic targets. Our tumor portfolio contains a number of proprietary, efficient and reproducible metastasis models.

We offer more than 50 different hematologic tumor lines, of both human and murine origin. We bring over a decade of industry-leading experience and expertise in model selection, study design, study execution, image acquisition and proprietary data analysis of disseminated tumor models.